Skip to main content

Advertisement

SpringerLink
Log in

Ganciclovir ophthalmic gel treatment shortens the recovery time and prevents complications in the adenoviral eye infection

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The purpose of this study was to determine the effectiveness of ganciclovir ophthalmic gel (GOG) in the treatment of adenoviral eye infection (AEI) by looking at the effect of the drug on shortening recovery time, preventing transmission, reducing sequelae, and on complications such as corneal infiltrates and conjunctival pseudomembranes. 200 patients’ examination records were evaluated retrospectively. Patients who were within the first 3 days of AEI were divided into two groups: Group 1 with 100 patients who used artificial tears as treatment, and Group 2 with 100 patients who used GOG plus artificial tears (GAT). All patients underwent an eye examination by the same ophthalmologist on the 1st, 5th, 10th, and 15th day after treatment. Using the examination records, variables were compared using SPSS 22.0. There was a statistically significant difference between Groups 1 and 2. Group 2 showed better and faster response to treatment. There was less transmission to the contralateral eye and environment, and less formation of corneal subepithelial infiltrate and conjunctival pseudomembrane in Group 2. Only three patients in Group 2 had corneal involvement. A comparison of each group pre-treatment and during treatment revealed improved signs and symptoms in Group 2 (p < 0.005). The study showed a trend toward more rapid improvement, less corneal and conjunctival involvement, and less transmission to the contralateral eye and environment in the GAT group. These results need to be confirmed by additional studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aoki K, Kaneko H, Nobuyoshi Kitaichi N et al (2011) Clinical features of adenoviral conjunctivitis at the early stage of infection. Jpn J Ophthalmol 55:11–15

    Article  CAS  PubMed  Google Scholar 

  2. Benko M, Harrach B, Both GW et al (2005) Family adenoviridae. Virus taxonomy. VIIIth report of the International Committee on Taxonomy of Viruses. Elsevier, New York, pp 213–228

    Google Scholar 

  3. Yağci R, Akçali A, Yağci S et al (2010) Molecular identification of adenoviral conjunctivitis in Turkey. Eur J Ophthalmol 20(4):669–674

    PubMed  Google Scholar 

  4. Azar MJ, Dhaliwal DK, Bower KS, Kowalski RP, Gordon YJ (1996) Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Am J Ophthalmol 121:711–712

    Article  CAS  PubMed  Google Scholar 

  5. Hillenkamp J, Reinhard T, Ross RS et al (2002) The effects of cidofovir 1 % with and without cyclosporin a 1 % as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 109:845–850

    Article  PubMed  Google Scholar 

  6. Kinchington PR, Romanowski EG, Gordon YJ (2005) Prospects for adenoviral antivirals. J Antimicrob Chemother 55:424–429

    Article  CAS  PubMed  Google Scholar 

  7. Tabbara KF, Jarade EF (2001) Ganciclovir effects in adenoviral keratoconjunctivitis [abstract 3111-B253]. ARVO 42:S579

    Google Scholar 

  8. Kaufman HE (2011) Adenovirus advances: new diagnostic and therapeutic options. Curr Opin Ophthalmol 22:290–293

    Article  PubMed  Google Scholar 

  9. Pihos AM (2013) Epidemic keratoconjunctivitis: a review of current concepts in management. J Optom 6(2):69–74

    Article  Google Scholar 

  10. Yabiku ST, Yabiku MM, Bottós KM, Araújo AL, Freitas Dd, Belfort R Jr (2011) Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis. Arq Bras Oftalmol 74(6):417–421

    Article  PubMed  Google Scholar 

  11. Affeldt J, Gadaria-Rathod N, Fernandez KB, Asbell P (2012) Ganciclovir in the treatment of ophthalmic viral infections—case reports. US Ophthalmic Rev 5(2):100–104

    Article  Google Scholar 

  12. Naesens G, Lenaerts L, Andrei G, Snoeck R, Van Beers D, Holy A (2005) Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 49(3):1010–1016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Colin J (2007) Ganciclovir ophthalmic gel, 00:15%: a valuable tool for treating ocular herpes. Clin Ophthalmol 1(4):441–453

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Markham A, Faulds D (1994) Gancyclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 48(3):455–484

    Article  CAS  PubMed  Google Scholar 

  15. Butt AL, Chodosh J (2006) Adenoviral keratoconjunctivitis in a tertiary care eye clinic. Cornea 25:199–202

    Article  PubMed  Google Scholar 

  16. Kowalski RP, Foulks GN, Gordon YJ (2000) An overview comparing treatment regimens for ocular infections: community versus academia. Ann Ophthalmol 32:295–300

    Article  Google Scholar 

  17. Lenaerts L, De Clercq E, Naesens L (2008) Clinical features and treatment of adenovirus infections. Rev Med Virol 18:357–374

    Article  CAS  PubMed  Google Scholar 

  18. Rajaiya J, Chodosh J (2006) New paradigms in infectious eye disease: adenoviral keratoconjunctivitis. Arch Soc Esp Oftalmol 81:493–498

    Article  CAS  PubMed  Google Scholar 

  19. Pelletier JS, Stewart K, Trattler W et al (2009) A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther 26:776–783

    Article  CAS  PubMed  Google Scholar 

  20. Gordon YJ, Araullo-Cruz T, Romanowski EG (1998) The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol 116:900–905

    Article  CAS  PubMed  Google Scholar 

  21. Shiuey Y, Ambati BK, Adamis AP et al (2000) A randomized, double-masked trial of topical ketorolac versus artificial tears from treatment of viral conjunctivitis. Ophthalmology 107:1512–1517

    Article  CAS  PubMed  Google Scholar 

  22. Romanowski EG, Pless P, Yates KA et al (2005) Topical cyclosporine A inhibits subepithelial infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea 24:86–91

    Article  PubMed  Google Scholar 

  23. Romanowski EG, Yates KA, Gordon YJ (2001) Short-term treatment with a potent topical corticosteroid of an acute ocular adenoviral infection in the New Zealand white rabbit. Cornea 20:657–660

    Article  CAS  PubMed  Google Scholar 

  24. de Oliveira B, Stevenson D, LaBree L, McDonnel PJ, Trousdale MD (1996) Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antivir Res 31(3):165–172

    Article  PubMed  Google Scholar 

  25. Uchio E, Fuchigami A, Kadonosono K et al (2007) Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 245(9):1319–1325

    Article  CAS  PubMed  Google Scholar 

  26. Hoh HB, Hurley C, Claoue C et al (1996) Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol 80(2):140–143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tabbara KF (2005) Treatment of herpetic keratitis. Ophthalmology 112(9):1640

    Article  PubMed  Google Scholar 

  28. Chen FE, Liang RH, Lo JY et al (1997) Treatment of adenovirus associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transpl 20:997–999

    Article  CAS  Google Scholar 

  29. Huang J, Kadonosono K, Uchio E (2014) Antiadenoviral effects of ganciclovir in types inducing keratoconjunctivitis by quantitative polymerase chain reaction methods. Clin Ophthalmol 8:315–320

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Piednoir E, Bureau-Chalot F, Merle C, Gotzamanis A, Wuiboult J, Bajolet O (2002) Direct costs associated with a nosocomial outbreak of adenoviral conjunctivitis infection in a long-term care institution. Am J Infect Control 30(7):407–410

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Surgical Sciences, Department of Ophthalmology, Faculty of Medicine, Giresun University, Debboy, 28100, Giresun, Turkey

    Serkan Ozen & Murat A. Ozer

Authors
  1. Serkan Ozen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murat A. Ozer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Serkan Ozen.

Ethics declarations

Conflict of interest

Ozen S and Ozer MA have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ozen, S., Ozer, M.A. Ganciclovir ophthalmic gel treatment shortens the recovery time and prevents complications in the adenoviral eye infection. Int Ophthalmol 37, 245–249 (2017). https://doi.org/10.1007/s10792-016-0260-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-016-0260-1

Keywords

Search

Navigation